Jeremy M. Merritt (merrittje@lilly.com) is currently a Senior director and group leader at Eli Lilly and Co. in the synthetic molecule design and development organization (SMDD).  He joined Lilly in 2009 and currently leads the Particle Design Lab (PDL) responsible for designing commercial isolation processes to enable physical property attributes for successful integration with drug product processing and particle size controls for absorption of both small molecules and peptides. His group is also active in furthering mechanistic impurity rejection understanding and the use of excipient-API coprocessing to enhance physical properties.  He was also part of the core commercialization team responsible for bringing the medicines Verzenio (Abemaciclib) and Retevmo (Selpercatinib) to patients.  Jeremy received his PhD in physical chemistry from the University of North Carolina at Chapel Hill and spent one month as an invited researcher at the Fritz-Haber Institute of the Max-Plank Society in the department of molecular physics (Berlin) before completing a postdoctoral appointment at Emory University.